The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society–USA Panel
Open accessAbstract
IMPORTANCE: New data and therapeutic options warrant updated recommendations for the use of antiretroviral drugs (ARVs) to treat or to prevent HIV infection in adults. OBJECTIVE: To provide updated recommendations for the use of antiretroviral therapy in adults (aged ≥18 years) with established HIV infection, including when to start treatment, initial regimens, and changing regimens, along with recommendations for using ARVs for preventing HIV among those at risk, including preexposure and postexposure prophylaxis. EVIDENCE REVIEW: A panel of experts in HIV research and patient care convened by the International Antiviral Society-USA reviewed data published in peer-reviewed journals, presented by regulatory agencies, or presented as conference abstracts at peer-reviewed scientific conferences since the 2014 report, for new data or evidence that would change previous recommendations or their ratings. Comprehensive literature searches were conducted in the PubMed and EMBASE databases through April 2016. Recommendations were by consensus, and each recommendation was rated by strength and quality of the evidence. FINDINGS: Newer data support the widely accepted recommendation that antiretroviral therapy should be started in all individuals with HIV infection with detectable viremia regardless of CD4 cell count. Recommended optimal initial regimens for most patients are 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus an integrase strand transfer inhibitor (InSTI). Other effective regimens include nonnucleoside reverse transcriptase inhibitors or boosted protease inhibitors with 2 NRTIs. Recommendations for special populations and in the settings of opportunistic infections and concomitant conditions are provided. Reasons for switching therapy include convenience, tolerability, simplification, anticipation of potential new drug interactions, pregnancy or plans for pregnancy, elimination of food restrictions, virologic failure, or drug toxicities. Laboratory assessments are recommended before treatment, and monitoring during treatment is recommended to assess response, adverse effects, and adherence. Approaches are recommended to improve linkage to and retention in care are provided. Daily tenofovir disoproxil fumarate/emtricitabine is recommended for use as preexposure prophylaxis to prevent HIV infection in persons at high risk. When indicated, postexposure prophylaxis should be started as soon as possible after exposure. CONCLUSIONS AND RELEVANCE: Antiretroviral agents remain the cornerstone of HIV treatment and prevention. All HIV-infected individuals with detectable plasma virus should receive treatment with recommended initial regimens consisting of an InSTI plus 2 NRTIs. Preexposure prophylaxis should be considered as part of an HIV prevention strategy for at-risk individuals. When used effectively, currently available ARVs can sustain HIV suppression and can prevent new HIV infection. With these treatment regimens, survival rates among HIV-infected adults who are retained in care can approach those of uninfected adults.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Self-citationPreexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Connor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M. J., VanDyke, R., Bey, M., Shearer, W., Jacobson, R. L., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311801 · Cited by 3,705
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
(2006) · PsycEXTRA Dataset · doi:10.1037/e545592006-001 · Cited by 2,958
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
The INSIGHT START Study Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506816 · Cited by 2,798
Sexually transmitted diseases treatment guidelines (2015)
Workowski, K., & BOLAN, G. A. (2015) · Reproductive Endocrinology · doi:10.18370/2309-4117.2015.24.51-56 · Cited by 2,698
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Self-citationCD4+ Count–Guided Interruption of Antiretroviral Treatment
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa062360 · Cited by 2,231
Cited by
Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., Sax, P. E., Smith, D. M., Thompson, M. A., Buchbinder, S. P., et al. (2018) · JAMA · doi:10.1001/jama.2018.8431 · Cited by 698
Self-citationMayer, K. H., Molina, J.-M., Thompson, M. A., Anderson, P. L., Mounzer, K. C., De Wet, J. J., DeJesus, E., Jessen, H., Grant, R. M., Ruane, P. J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31065-5 · Cited by 428
Self-citation2015 update of the drug resistance mutations in HIV-1
Wensing, A. M. J., Cálvez, V., Ceccherini‐Silberstein, F., Charpentier, C., Günthard, H. F., Jacobsen, D. M., Paredes, R., Shafer, R. W., & Richman, D. D. (2015) · PubMed · doi:10.5167/uzh-122257 · Cited by 415
Self-citationSax, P. E., Pozniak, A., Montes, M. L., Koenig, E., DeJesus, E., Stellbrink, H.-J., Antinori, A., Workowski, K., Slim, J., Reynes, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32340-1 · Cited by 396
Self-citationGallant, J., Lazzarin, A., Mills, A., Orkin, C., Podzamczer, D., Tebas, P., Girard, P.-M., Brar, I., Daar, E. S., Wohl, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32299-7 · Cited by 393
Self-citationBarouch, D. H., Tomaka, F. L., Wegmann, F., Stieh, D. J., Alter, G., Robb, M. L., Michael, N. L., Peter, L., Nkolola, J. P., Borducchi, E. N., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31364-3 · Cited by 336
Ghosn, J., Taiwo, B., Seedat, S., Autran, B., & Katlama, C. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31311-4 · Cited by 306
The Placental Barrier: the Gate and the Fate in Drug Distribution
Tetro, N., Moushaev, S., Rubinchik-Stern, M., & Eyal, S. (2018) · Pharmaceutical Research · doi:10.1007/s11095-017-2286-0 · Cited by 145
Tettamanti Boshier, F. A., Srinivasan, S., Lopez, A., Hoffman, N. G., Proll, S., Fredricks, D. N., & Schiffer, J. T. (2020) · mSystems · doi:10.1128/msystems.00777-19 · Cited by 97
Pantalone, D. W., Nelson, K. M., Batchelder, A. W., Chiu, C., Gunn, H. A., & Horvath, K. J. (2020) · The Journal of Sex Research · doi:10.1080/00224499.2020.1728514 · Cited by 81
“…category has been an especially prolific area of behavioral intervention research, given the high levels of medication adherence needed to maintain virologic control (>75% of prescribed doses, depending on regimen; Byrd et al., 2019) and the indefinite treatment duration (Günthard et al., 2016).”
BackgroundSamad, F., Harris, M., Puskas, C. M., Ye, M., Chia, J., Chacko, S., Bondy, G. P., Lima, V. D., Montaner, J. S., & Guillemi, S. A. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000457 · Cited by 53
Guan, M., Lim, L., Holguin, L., Han, T., Vyas, V., Urak, R., Miller, A., Browning, D. L., Echavarria, L., Li, S., et al. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.04.007 · Cited by 21
Mimtsoudis, I., Tsachouridou, O., Akinosoglou, K., & Metallidis, S. (2024) · Viruses · doi:10.3390/v16091392 · Cited by 13
“In addition, in coinfection with HIV and HBV, the use of TDF/3TC or FTC is suggested for first-line ART regimens [17–21].”
BackgroundGarcia, L. P., Van de Wijer, L., Hanswijk, S. I., Rando, J., Witteveen, J. S., Middelman, A., ter Heine, R., de Mast, Q., Martens, G. J. M., van der Ven, A. J. A. M., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114050 · Cited by 6
Metadata
- Authors
- Günthard, H. F., Saag, M. S., Benson, C. A., del Rio, C., Eron, J. J., Gallant, J. E., Hoy, J. F., Mugavero, M. J., Sax, P. E., Thompson, M. A., Gandhi, R. T., Landovitz, R. J., Smith, D. M., Jacobsen, D. M., & Volberding, P. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-07-12
- Volume
- 316
- Issue
- 2
- Pages
- 191
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2467247336
- Cited by
- 656
- References
- 153
- FWCI
- 106.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.